Abstract:The Janus kinase 2 (JAK2) gene is located on chromosome 9p24.1 and encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signaling. The JAK2 protein is especially important for controlling the production of blood cells from hematopoietic stem cells. In fact, the JAK2 mutation at amino acid 617 (Valine 617 to Phenylalanine, V617F) is the most frequently detected mutation in myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). This dominant gain-of-function V617F mutation results in constitutive tyrosine phosphorylation activity, leading to uncontrolled blood cell production, including increased numbers of erythrocytes, neutrophils, and platelets. To detect the JAK2 V617F mutation in DNA from patient blood samples, we developed a unique real-time PCR assay using our proprietary XNA technology that enables the assay to selectively amplify the mutant sequence by using a synthetic DNA analog XNA (Xenonucleic Acid). The JAK2 V617F mutation detection assay is designed to detect a valine-to-phenylalanine mutation at amino acid 617 (V617F). PCR primers, TaqMan probes, and XNA were designed for the JAK2 V617F mutation, along with primers and probes for an internal control gene in the duplex setting. The analytical performance of the assay was verified and validated using a variety of control samples. The results revealed that the XNA completely suppressed the amplification of wildtype sequence while only the V617F mutant sequence was amplified. The JAK2 V617F mutation detection assay is highly reproducible with intra- and inter-assay coefficients of variation of less than 10%. Results for the assay's analytical sensitivity indicated that V617F could be detected with about 0.25% mutant allele frequency in 10 ng DNA input. In addition, no significant cross-amplification between V617F and V617I was observed. Thus, the JAK2 V617F mutation detection assay is specific for the V617F mutation. The JAK2 V617F mutation detection assay, using XNA-based technology, provides high sensitivity and specificity to detect the JAK2 V617F mutation. Thus, this assay would be a useful tool for clinical decision-making in determining the presence of the JAK2 V617F mutation in DNA from patient blood samples. Citation Format: Shuo Shen, Robert Brown, Daniel Kim, Larry Pastor, Andrew Y. Fu, Pushpinder Kaur, Alisha Babu, Wei Liu, Aiguo Zhang, Hiromi Tanaka, Michael Y. Sha. A novel XNA technology-based assay to detect JAK2 V617F mutation by real-time PCR [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7295.

Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

Detecting JAK2 V617F Mutation in Myeloproliferative Neoplasms by Microarray Based Digital PCR

Toward point-of-care testing for JAK2 V617F mutation on a microchip

A portable microfluidic platform for rapid molecular diagnostic testing of patients with myeloproliferative neoplasms

Quantification of JAK2V617F Mutation Load by Droplet Digital PCR Can Aid in Diagnosis of Myeloproliferative Neoplasms

Detection of the Jak2 Mutation in Myeloproliferative Neoplasms by Asymmetric Pcr with Unlabeled Probe and High-Resolution Melt Analysis

Clinical Analysis of JAK2 V617F Gene Mutation in 120 Patients with Myeloproliferative Neoplasms

Crispr/Cas12a-Based Ultrasensitive And Rapid Detection Of Jak2 V617f Somatic Mutation In Myeloproliferative Neoplasms

Establishment of Scalable Nanoliter Digital LAMP Technology for the Quantitative Detection of Multiple Myeloproliferative Neoplasm Molecular Markers

Development And Inter-Laboratory Validation Of Unlabeled Probe Melting Curve Analysis For Detection Of Jak2 V617f Mutation In Polycythemia Vera

A Multiplex Snapback Primer System for the Enrichment and Detection Ofjak2v617f Andmplw515l/k Mutations in Philadelphia-Negative Myeloproliferative Neoplasms

Performance evaluation of the automated SNPs analyzer for the detection of JAK2 V617F mutation

Clinical significance of JAK2,CALR and MPL gene mutations in 132 myeloproliferative neoplasms patients with BCR-ABL fusion gene negative

A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms.

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

[Detection of JAK2V617F Mutation in Patients with Myeloproliferative Disorders with TaqMan-MGB Probe].

Detection of JAK2 V617F Mutation by Real-Time PCR

A Quantitative Assay for JAK2 Mutation in 135 Patients with Chronic Myeloproliferative Neoplasms

Abstract 7295: A novel XNA technology-based assay to detect JAK2 V617F mutation by real-time PCR

MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes.